MX2022006737A - Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. - Google Patents

Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Info

Publication number
MX2022006737A
MX2022006737A MX2022006737A MX2022006737A MX2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A
Authority
MX
Mexico
Prior art keywords
peptide
gip
dependent insulinotropic
glucose
optimized
Prior art date
Application number
MX2022006737A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Hovard Sparre-Ulrich
Ditte Riber
Mette Marie Rosenkilde
Samra Joke Sanni
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of MX2022006737A publication Critical patent/MX2022006737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022006737A 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. MX2022006737A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
MX2022006737A true MX2022006737A (es) 2022-06-14

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006737A MX2022006737A (es) 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Country Status (10)

Country Link
US (1) US20250346647A2 (enExample)
EP (1) EP4069719A1 (enExample)
JP (2) JP7788376B2 (enExample)
KR (1) KR20220108064A (enExample)
CN (1) CN114761420B (enExample)
AU (1) AU2020398675A1 (enExample)
CA (1) CA3157387A1 (enExample)
IL (1) IL293249A (enExample)
MX (1) MX2022006737A (enExample)
WO (1) WO2021110845A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IN2014MN02304A (enExample) * 2012-05-03 2015-08-07 Zealand Pharma As
ES2685987T3 (es) * 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
SG11202105586YA (en) * 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CA3157387A1 (en) 2021-06-10
CN114761420B (zh) 2026-04-28
WO2021110845A1 (en) 2021-06-10
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
JP7788376B2 (ja) 2025-12-18
KR20220108064A (ko) 2022-08-02
AU2020398675A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2022006737A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.
MX2021006505A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
PE20210162A1 (es) Analogos de incretina y sus usos
CL2020002034A1 (es) Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CY1121032T1 (el) Παραγωγα εξενδινης-4 ως επιλεκτικοι αγωνιστες υποδοχεα γλυκαγονης
EP3870593A4 (en) NUCLEOTIDE ANALOGUES
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
DK4122954T3 (da) Novel GLP-1-analoger
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
BR112019025195A8 (pt) análogos do peptídeo gip de ação prolongada
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
IL285547A (en) Long-acting glp-2 analogs
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2022001227A1 (es) Agonistas del receptor npy2
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger
MX2022008016A (es) Compuesto antagonista de pd-l1.
EP3917933A4 (en) DUOCARMYCIN ANALOGUES